Literature DB >> 19952421

Effects of Kampo medicines on P-glycoprotein.

Toshiyuki Satoh1, Yuka Watanabe, Nobutomo Ikarashi, Kiyomi Ito, Kiyoshi Sugiyama.   

Abstract

The Kampo medicines are more and more often used in recent years, usually together with the western drugs. The need for the investigation of drug interactions between Kampo medicines and western drugs are, therefore, widely recognized. Among the various possible causes for the drug-drug interactions, those related to pharmacokinetics such as drug metabolism and transport are regarded as most frequent and clinically important. In the present study, the effects of Kampo medicines on the P-glycoprotein (P-gp), one of the major drug transporters, were investigated in in vitro studies using human P-gp membranes. The P-gp activity in the presence and absence of commonly used 50 Kampo medicines was evaluated by the ATPase assay detecting the inorganic phosphate produced by the ATP hydrolysis. The ATPase activity was inhibited by most of the Kampo medicines studied, indicating the possibility of their inhibiting the P-gp. The degree of inhibition in the presence of verapamil, a P-gp substrate, showed a significant correlation with that in the absence of verapamil. Furthermore, the inhibitory effect of the Kampo medicines on the ATPase activity correlated with their licorice root (kanzo) content, suggesting the contribution of licorice root in the P-gp inhibition. Because licorice root is one of the most common ingredients in the Kampo medicines and is also often used in the food as a sweetener, it might be necessary to pay attention on the interaction between the licorice root-containing drug/food and the number of drugs transported by P-gp.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19952421     DOI: 10.1248/bpb.32.2018

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  4 in total

1.  Use of a Caco-2 permeability assay to evaluate the effects of several Kampo medicines on the drug transporter P-glycoprotein.

Authors:  Takashi Matsumoto; Noriko Kaifuchi; Yasuharu Mizuhara; Eiji Warabi; Junko Watanabe
Journal:  J Nat Med       Date:  2018-05-24       Impact factor: 2.343

2.  Inhibitory effects of daiokanzoto (da-huang-gan-cao-tang) on p-glycoprotein.

Authors:  Yuka Watanabe; Nobutomo Ikarashi; Toshiyuki Satoh; Kiyomi Ito; Wataru Ochiai; Kiyoshi Sugiyama
Journal:  Evid Based Complement Alternat Med       Date:  2012-08-27       Impact factor: 2.629

3.  Concerns regarding the use of dabigatran for stroke prevention in atrial fibrillation.

Authors:  Claudia Stöllberger; Josef Finsterer
Journal:  Pharmaceuticals (Basel)       Date:  2012-02-03

4.  Alleviating the Intestinal Absorption of Rhein in Rhubarb through Herb Compatibility in Tiaowei Chengqi Tang in Caco-2 Cells.

Authors:  Ying Peng; Min Fan; Chongsheng Peng; Mengyue Wang; Xiaobo Li
Journal:  Evid Based Complement Alternat Med       Date:  2018-01-30       Impact factor: 2.629

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.